Actinium Pharma Analyst Ratings
Actinium Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/03/2023 | 247.52% | B. Riley Securities | → $20 | Reiterates | Buy → Buy |
| 09/07/2023 | 768.81% | HC Wainwright & Co. | → $50 | Reiterates | Buy → Buy |
| 09/06/2023 | 101.56% | HSBC | → $11.6 | Initiates Coverage On | → Buy |
| 08/15/2023 | 768.81% | HC Wainwright & Co. | $53 → $50 | Maintains | Buy |
| 05/16/2023 | 820.94% | HC Wainwright & Co. | → $53 | Reiterates | Buy → Buy |
| 04/20/2023 | 820.94% | HC Wainwright & Co. | → $53 | Reiterates | → Buy |
| 02/21/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 02/21/2023 | 820.94% | HC Wainwright & Co. | → $53 | Reiterates | → Buy |
| 02/07/2023 | 820.94% | HC Wainwright & Co. | → $53 | Reiterates | → Buy |
| 10/31/2022 | 212.77% | B. Riley Securities | $16 → $18 | Maintains | Buy |
| 10/31/2022 | 820.94% | HC Wainwright & Co. | $45 → $53 | Maintains | Buy |
| 09/08/2022 | 247.52% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 08/25/2022 | 178.02% | B. Riley Securities | → $16 | Initiates Coverage On | → Buy |
| 08/03/2021 | 681.93% | HC Wainwright & Co. | $57 → $45 | Maintains | Buy |
| 04/01/2021 | 890.44% | HC Wainwright & Co. | $65 → $57 | Maintains | Buy |
| 06/04/2020 | -47.87% | HC Wainwright & Co. | → $3 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/03/2023 | 247.52% | B.萊利證券 | →$20 | 重申 | 購買→購買 |
| 09/07/2023 | 768.81% | HC Wainwright公司 | →$50 | 重申 | 購買→購買 |
| 09/06/2023 | 101.56% | 匯豐銀行 | →$11.6 | 開始承保 | →購買 |
| 2023年08月15日 | 768.81% | HC Wainwright公司 | $53→$50 | 維護 | 買 |
| 2023年05月16日 | 820.94% | HC Wainwright公司 | →$53 | 重申 | 購買→購買 |
| 04/20/2023 | 820.94% | HC Wainwright公司 | →$53 | 重申 | →購買 |
| 02/21/2023 | - | 威廉·布萊爾 | 評級下調 | 跑贏→市場表現 | |
| 02/21/2023 | 820.94% | HC Wainwright公司 | →$53 | 重申 | →購買 |
| 02/07/2023 | 820.94% | HC Wainwright公司 | →$53 | 重申 | →購買 |
| 2022年10月31日 | 212.77% | B.萊利證券 | $16→$18 | 維護 | 買 |
| 2022年10月31日 | 820.94% | HC Wainwright公司 | $45→$53 | 維護 | 買 |
| 09/08/2022 | 247.52% | 康託·菲茨傑拉德 | →$20 | 開始承保 | →超重 |
| 2022年08月25日 | 178.02% | B.萊利證券 | →$16 | 開始承保 | →購買 |
| 08/03/2021 | 681.93% | HC Wainwright公司 | $57→$45 | 維護 | 買 |
| 04/01/2021 | 890.44% | HC Wainwright公司 | $65→$57 | 維護 | 買 |
| 06/04/2020 | -47.87% | HC Wainwright公司 | →$3 | 開始承保 | →購買 |
What is the target price for Actinium Pharma (ATNM)?
Actdium Pharma(ATNM)的目標價是多少？
The latest price target for Actinium Pharma (AMEX: ATNM) was reported by B. Riley Securities on October 3, 2023. The analyst firm set a price target for $20.00 expecting ATNM to rise to within 12 months (a possible 247.52% upside). 11 analyst firms have reported ratings in the last year.
B.Riley Securities於2023年10月3日報告了Actdium Pharma(美國證券交易所代碼：ATNM)的最新目標價。這家分析公司將目標價定為20美元，預計ATNM將在12個月內上漲至(可能上漲247.52%)。過去一年，有11家分析公司公佈了評級。
What is the most recent analyst rating for Actinium Pharma (ATNM)?
Actdium Pharma(ATNM)的最新分析師評級是多少？
The latest analyst rating for Actinium Pharma (AMEX: ATNM) was provided by B. Riley Securities, and Actinium Pharma reiterated their buy rating.
Actdium Pharma(美國證券交易所代碼：ATNM)的最新分析師評級由B.Riley Securities提供，Actdium Pharma重申其買入評級。
When is the next analyst rating going to be posted or updated for Actinium Pharma (ATNM)?
Actdium Pharma(ATNM)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Actinium Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Actinium Pharma was filed on October 3, 2023 so you should expect the next rating to be made available sometime around October 3, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查看公開的財務報表，與Actdium Pharma的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Actdium Pharma的上一次評級是在2023年10月3日提交的，因此您應該預計下一次評級將在2024年10月3日左右的某個時候提供。
Is the Analyst Rating Actinium Pharma (ATNM) correct?
分析師對Actdium Pharma(ATNM)的評級正確嗎？
While ratings are subjective and will change, the latest Actinium Pharma (ATNM) rating was a reiterated with a price target of $0.00 to $20.00. The current price Actinium Pharma (ATNM) is trading at is $5.76, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Actdium Pharma(ATNM)評級被重申，目標價在0.00美元至20.00美元之間。Actdium Pharma(ATNM)目前的交易價格為5.76美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。